Rare diseases are defined as those that affect one person in 2,000, or around three million people in France. The majority of rare diseases are caused by genetics and tend to be severe when they begin in childhood. Autoimmune and autoinflammatory diseases, such as systemic lupus, juvenile dermatomyositis, and juvenile idiopathic arthritis, are examples of rare pediatric diseases. While autoimmune diseases are characterized by an inappropriate adaptive immune response, autoinflammatory diseases involve an excess of the innate immune response. The precise mechanisms of these diseases are not yet fully understood, but recent research has led to advances in their diagnosis and identification, particularly in early onset and familial forms. However, the rarity of these diseases and limited availability of biological samples pose significant challenges. This study aims to create a biological collection, which includes primary cells (PBMC), DNA, RNA, lymphoblastic lines, and serum, that will help identify genetic and immunological abnormalities in rare autoimmune and autoinflammatory diseases through various research projects.
A disease is said to be "rare" when it affects one person in 2,000, which represents three million people in France. Most rare diseases (80%) are genetic in origin ; the earlier they start in childhood, the more severe they can be. Rare pediatric diseases include autoimmune diseases (systemic lupus, juvenile dermatomyositis and juvenile idiopathic arthritis) and autoimmune diseases (interferonopathies, FMF, CAPS, TRAPS, and DADA2). Systemic autoimmune diseases are characterized by an inappropriate adaptive immune response (mediated by autoreactive T and/or B lymphocytes) with the production of autoantibodies directed against the constituents of the self (tolerance breakdown). Autoinflammatory diseases, unlike autoimmune diseases, correspond to an excess in the innate immune response (cytokines, macrophages, NK cells, granulocytes, etc.)..The precise pathophysiological mechanisms of these diseases have yet to be fully elucidated. Recent research has led to advances in the diagnosis and identification of monogenic forms of these diseases, particularly in early onset, familial, and syndromic forms. Nevertheless, the rarity of these diseases and limited availability of biological samples are major challenges that need to be overcome. Thus, the aims of this study were as follows: \- The creation of a biological collection: primary cells (PBMC), DNA, RNA, lymphoblastic lines, and serum, which, through various research projects, will help identify genetic and immunological abnormalities in rare autoimmune and autoinflammatory diseases.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
400
genetic analysis (WES, WGS) for the identification of germline and somatic mutations responsible for rare autoimmune diseases or auto-inflammatory pathologies (pediatric or syndromic or familial) that began in childhood
Identifying specific immunological factors in patients with rare pediatric autoimmune and auto inflammatory diseases
Research biomarkers for diagnosis, prognosis and monitoring of disease activity
Service de rhumatologie pédiatrique Hôpital Femme-Mère-enfant
Bron, Bron, France
RECRUITINGHôpital Jeanne de Flandre (CHU de Lille)
Lille, Lille, France
NOT_YET_RECRUITINGHôpital Claude Huriez (CHU de Lille)
Lille, Lille, France
NOT_YET_RECRUITINGHôpital Archet 2
Nice, Nice, France
NOT_YET_RECRUITINGHôpital Necker-Enfants Malades (AP-HP)
Paris, Paris, France
NOT_YET_RECRUITINGHôpital Robert Debré (AP-HP)
Paris, Paris, France
NOT_YET_RECRUITINGHôpital Kremlin-Bicêtre (AP-HP)
Paris, Paris, France
NOT_YET_RECRUITINGHôpital Nord (CHU ST-Etienne)
Saint-Etienne, Saint Etienne, France
NOT_YET_RECRUITINGHôpital Couple Enfant
Grenoble, France
NOT_YET_RECRUITINGDr Isabelle MELKI
Paris, France
RECRUITING...and 3 more locations
To Identify germline and somatic mutations responsible for rare autoimmune diseases or auto-inflammatory pathologies (pediatric or syndromic or familial) that began in childhood
Identification of germline or somatic genetic mutations, based on high-throughput sequencing data (exome, genome or transcriptome).
Time frame: Baseline
Measurement of disease activity according to Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
score (Min value: 0 - Max value: 105), with higher values mean higher disease activity
Time frame: Baseline
Levels of anti-double stranded DNA
in patients sera
Time frame: Baseline
Levels of complement components C3 and C4
in patients sera
Time frame: Baseline
Level of IFN Signature score
Mesured by 6-gene Type 1 IFN Signature Score
Time frame: Baseline
Concentration of circulating IFN-alpha
In serum using single-molecule array digital ELISA technology (Simoa)
Time frame: Baseline
Presence or absence of anti-type I interferons autoantibodies
in patients sera
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.